Elias, Sjoerd

Elkhuizen, Paula

Gort, Eelke

Ho, Vincent

Linn, Sabine

Siesling, Sabine

Visser, Otto

English

University of Twente Research Information

14-11-2014 | S. Siesling  Otto Visser, MD PhD Head of Cancer Registration Netherlands Comprehensive Cancer Organisation (IKNL)  THE ORDER OF RADIOTHERAPY AND CHEMOTHERAPY IN EARLY BREAST CANCER AND ITS EFFECT ON OUTCOME On behalve of: NKI-AVL, Amsterdam • Eelke Gort,  • Sjoerd Elias,  • Paula Elkhuizen, • Sabine Linn Julius Centre, UMCU, Utrecht • Sjoerd Elias Netherlands Comprehensive Cancer Organization (IKNL) • Sabine Siesling • Vincent Ho • Otto Visser   Background • Early breast cancer patients with unfavourable prognostic factors are often treated with both chemotherapy (CT) and radiotherapy (RT).  • Delay in the start of RT or CT may result in increased risk of locoregional and/or distant recurrence. • The optimal sequence of RT and CT is subject for debate.     Background • Concurrent  administration of RT and CT might improve locoregional control • Concurrent CT and RT is not advised in the Netherlands because of the excess risk of treatment-related side effects  • Studies until now are often preformed with selected (small) populations • Sequencing in the Netherlands was arbitrary and not according to national guidelines    Aim of the study Determine the effect of RT and CT sequence on overall survival (OS) and recurrence-free survival (RFS) using a large dataset from a population-based cancer registry.  Materials & methods  • Cases selected from the Netherlands Cancer Registry • All primary breast cancers diagnosed 1999-2008  • Cox and competing risk regression was used to compare OS and RFS in two treatment groups  - RT first - CT first • adjustment for important prognostic variables  Selection of cases • 131,122 primary breast cancers in 1999-2008 - Exclusion: Tis, TX, T4, M1, second breast cancers, no surgery, neo-adjuvant treatment • 93,399 T1-3M0 treated with surgery  - Exclusion: no combination of RT and CT • 22,045 primary breast cancer patients received both CT and RT (after surgery) - 9,977 (45%) received RT first - 2,068 (55%) received CT first.  - during a total of 112,872 patient years of follow-up (median 57 months), 3,075 patients died.  Distributions of the treatment options Ratio RT/CT first over the years Results Overall survival (OS) Overall survival (OS) • adjustments for age, stage, number of positive lymph nodes, histological grade and administration of hormone therapy: - no survival difference for CT first compared to RT first (hazard ratio (HR) 0.97; 95%CI 0.90-1.05; P=0.46).  • Additional adjustment for hormone receptor status, HER2 status and tumor diameter available for a subgroup of 9,951 patients: - confirmation of these results (HR 0.96; 95%CI 0.79-1.16; P=0.66).   OS according to type of surgery OS according to nr of positive lymph nodes Disease-free survival (DFS) • In 6,582 patients data on recurrent disease were specifically documented (period 2003-2006) • 30,762 patient years of follow-up (median 61 months) • 1,259 patients experienced one or more recurrences  Recurrence type documented in the recurrence cohort Disease-free survival (DFS) • No significant recurrence-free survival benefit was seen for either treatment sequence (HR 0.97; 95%CI 0.86-1.10; P=0.64).  RFS according to type of surgery RFS according to nr of positive lymph nodes Conclusion A large analysis of prospectively collected cancer registry data of primary breast cancer patients after a median follow-up of approximately 5 years   The sequence of radio- and chemotherapy as practiced in routine clinical care did not affect overall-survival or recurrence-free survival    www.iknl.nl www.linkedin.com/company/iknl twitter.com/iknl CT-RT sequence in relation to OS in the full cohort and 2005 cohort 

The order of radiotherapy and chemotherapy in early breast cancer and its effect on outcome

NARCIS 

The order of radiotherapy and chemotherapy in early breast cancer and its effect on outcome

Abstract

Similar works

Full text

Available Versions

University of Twente Research Information

NARCIS